Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
Critical Care Center, Seoul National University Hospital, Seoul, Korea.
Ann Surg Oncol. 2019 Sep;26(9):2905-2911. doi: 10.1245/s10434-019-07455-z. Epub 2019 Jun 12.
Understanding the natural progression of untreated gastric cancer is critical for determining the disease prognosis as well as treatment options and timing. The aim of this study is to analyze the natural history of gastric cancer.
We included patients with gastric cancer who had not received any treatment and were staged using endoscopy/endoscopic ultrasonography and computed tomography on at least two follow-up visits during intervals of nontreatment. Tumor volumes were also measured in addition to the staging. Survival of each stage at diagnosis was also analyzed.
A total of 101 patients were included. The mean follow-up period was 35.1 ± 34.4 months. The gastric cancer doubling time was 11.8 months for T1 and 6.2 months for T4. The progression time from early gastric cancer to advanced gastric cancer was 34 months. It decreased as the stages advanced: from 34 months between tumor-nodes-metastasis stage I and II to 1.8 months between stage III and IV. No variable was identified as a risk factor for cancer progression. The 5-year survival rates of untreated patients were 46.2% in stage I and 0% in stage II, stage III, and stage IV.
The progression and doubling times of gastric cancer shorten as the stages advance. Objective data reported in this study can be a critical factor in determining treatment timing and screening interval.
了解未经治疗的胃癌的自然病程对于确定疾病的预后以及治疗方案和时机至关重要。本研究旨在分析胃癌的自然史。
我们纳入了未经任何治疗且在非治疗期间至少两次随访中通过内镜/内镜超声和计算机断层扫描分期的胃癌患者。除分期外,还测量了肿瘤体积。还分析了每个诊断阶段的生存情况。
共纳入 101 例患者。平均随访时间为 35.1±34.4 个月。T1 的胃癌倍增时间为 11.8 个月,T4 的胃癌倍增时间为 6.2 个月。从早期胃癌进展为晚期胃癌的时间为 34 个月。随着分期的进展而缩短:从肿瘤-淋巴结-转移 I 期和 II 期之间的 34 个月到 III 期和 IV 期之间的 1.8 个月。没有变量被确定为癌症进展的危险因素。未经治疗的患者的 5 年生存率在 I 期为 46.2%,在 II 期、III 期和 IV 期均为 0%。
胃癌的进展和倍增时间随着分期的进展而缩短。本研究报告的客观数据可能是确定治疗时机和筛查间隔的关键因素。